Compare YHC & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHC | OGEN |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.3M |
| IPO Year | 2023 | 2010 |
| Metric | YHC | OGEN |
|---|---|---|
| Price | $1.33 | $0.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 40.4K | 26.8K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.28 | N/A |
| Revenue | ★ $1,120,622.00 | N/A |
| Revenue This Year | $1,267.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | ★ 86.42 | N/A |
| 52 Week Low | $0.02 | $0.48 |
| 52 Week High | $2.72 | $1.45 |
| Indicator | YHC | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 43.89 |
| Support Level | $1.27 | $0.49 |
| Resistance Level | $2.20 | $0.59 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 24.00 | 33.92 |
LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.